Archives
-
Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok
2026-07-23
This study demonstrates the use of M2 microglia-targeted lipid nanoparticles to deliver IL-10 mRNA, promoting microglial polarization, resolving neuroinflammation, and repairing the blood-brain barrier after ischemic stroke. The findings highlight a promising, selective mRNA therapeutic strategy that extends the poststroke intervention window.
-
Berberine Hydrochloride Induces Tuft Cells to Counter Bone L
2026-07-23
A 2026 study demonstrates that berberine hydrochloride alleviates estrogen deficiency-associated bone loss by inducing intestinal tuft cell expansion via increased butyrate production and GPR41 signaling. This work introduces a novel gut–bone axis mechanism with implications for postmenopausal osteoporosis research and osteoimmune regulation.
-
Oxidative Modification of Hazelnut Proteins: Effects on Func
2026-07-22
This study systematically compared the impact of distinct oxidative agents—including AAPH, malondialdehyde (MDA), and hydrogen peroxide—on the functional and gel-forming properties of hazelnut proteins. Findings clarify how specific radical-driven processes alter protein solubility, emulsification, and gel network structure, with implications for food processing and oxidative stress modeling.
-
Hematoxylin and Eosin Staining Kit: Practical Protocols and
2026-07-22
The Hematoxylin and Eosin Staining Kit (SKU: K1142) provides ready-to-use staining solutions for reliable tissue morphology visualization in paraffin-embedded and frozen sections. It is intended for research laboratories requiring reproducible nuclear and cytoplasmic staining workflows. The kit is not suitable for diagnostic or clinical use and should not be applied outside experimentally controlled research settings.
-
Intravesical p21 mRNA-LNP Therapy: A Targeted Approach for B
2026-07-21
This study demonstrates that localized, intravesical delivery of p21 mRNA–loaded lipid nanoparticles (LNPs) can restore tumor suppressor function and suppress tumor growth in non–muscle-invasive bladder cancer models. The findings highlight an innovative, clinically compatible strategy for tumor suppressor replacement, overcoming delivery and specificity challenges of mRNA therapeutics.
-
Partial β-Secretase Inhibition Preserves Synaptic Function i
2026-07-21
Satir et al. (2020) demonstrate that moderate β-secretase (BACE) inhibition can reduce amyloid β production by up to 50% without impairing synaptic transmission in primary neuronal cultures. This finding suggests a therapeutic window for BACE inhibitors in Alzheimer's disease that minimizes risk to synaptic physiology.
-
AAPH and Ferroptosis: Redefining Lipid Peroxidation Assays
2026-07-20
Explore how AAPH (2,2'-Azobis(2-methylpropionamidine) dihydrochloride) enables advanced, reproducible in vitro models of lipid peroxidation and ferroptosis. This article uniquely bridges oxidative stress chemistry with translational cancer research insights.
-
Clarithromycin as a Benchmark CYP3A Inhibitor in Drug-Drug I
2026-07-20
Clarithromycin enables high-precision drug-drug interaction and pharmacokinetic studies by serving as a robust CYP3A inhibitor, essential for evaluating statin metabolism and cardiovascular drug safety. This article details actionable workflows, troubleshooting strategies, and experimental insights to maximize reproducibility and interpretability when using APExBIO's Clarithromycin reagent.
-
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution
2026-07-19
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a rapid, reliable method for nuclear visualization and cell viability assessment in fixed or membrane-compromised cells. It should not be used for live-cell imaging due to limited membrane permeability but is well-suited for fluorescence microscopy and flow cytometry workflows.
-
MK-5108 (VX-689): Precision Aurora A Inhibition in Oncology
2026-07-18
MK-5108 (VX-689) delivers nanomolar selectivity for Aurora A kinase, enabling high-fidelity dissection of cell cycle and tumor proliferation in advanced cancer models. This guide translates recent retinoblastoma findings into actionable workflows, troubleshooting, and protocol enhancements using APExBIO’s highly selective inhibitor.
-
Clodronate Liposomes: Precision In Vivo Macrophage Depletion
2026-07-17
Clodronate Liposomes deliver targeted, reproducible in vivo macrophage depletion, enabling researchers to dissect immune cell functions and model therapy resistance. This article details optimized workflows, experimental troubleshooting, and translational applications, spotlighting their impact on tumor immunology and beyond.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Real-Time mRNA Delivery Ins
2026-07-17
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) unlocks dual-fluorescence, immune-evasive mRNA tracking for rigorous gene delivery, function, and translation efficiency studies. Direct Cy5 and EGFP readouts streamline experimental workflows and enable rapid troubleshooting in nanoparticle optimization, immune activation research, and transfection monitoring.
-
Linoleic Acid (C18:2): Beyond Oxidative Stress to Translatio
2026-07-16
Explore how Linoleic Acid (C18:2(9Z,12Z)) enables pioneering research in membrane biology, oxidative stress, and translational control. This article reveals how new mechanistic insights connect essential fatty acid metabolism to advanced assay design and cancer research.
-
O-propargyl-puromycin (OPP): Precision Protein Synthesis Ana
2026-07-16
O-propargyl-puromycin (OPP) empowers researchers to quantitatively map nascent protein synthesis with single-cell and subcellular resolution, thanks to its unique alkyne functionality and compatibility with click chemistry. This article details advanced experimental workflows, practical troubleshooting, and actionable insights that connect mitochondrial regulation in B cells to optimized proteomics research.
-
25-Hydroxycholesterol, AMPK, and Macrophage Immunosuppressio
2026-07-15
Xiao et al. (2024) reveal that 25-hydroxycholesterol (25HC) accumulation in tumor-associated macrophages (TAMs) activates AMP kinase via a lysosome-dependent pathway, driving immunosuppressive phenotypes and metabolic reprogramming. Targeting the enzyme CH25H, which produces 25HC, disrupts these pathways and enhances anti-tumor immune responses, offering new avenues for immunometabolic intervention.